A Study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of CT-P53 and Ocrevus in Patients With Relapsing-remitting Multiple Sclerosis

This study is comparing a biosimilar drug (CT-P53) to the brand-name medication Ocrevus (ocrelizumab) in people with relapsing-remitting multiple sclerosis (MS). A biosimilar is a near-identical version of an approved drug. The study aims to confirm that CT-P53 works the same way and is equally safe. **You may be eligible if...** - You have been diagnosed with relapsing-remitting MS - You have had recent MS activity (as defined by the study protocol) - Your neurological condition has been stable for at least 30 days - Your disability score (EDSS) is between 0 and 6.0 **You may NOT be eligible if...** - You have primary or secondary progressive MS - You have had MS for more than 15 years with a low disability score - You cannot have an MRI scan - You have an allergy to corticosteroids or the study drug - You are on or have taken medications that are prohibited per the study protocol Talk to your doctor to see if this trial is right for you.